Henry Tran1, Jaime Kwok1, Tom Pickles2, Scott Tyldesley2, Peter C Black3. 1. Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. 2. Department of Radiation Oncology, Vancouver Cancer Center, BC Cancer Agency, Vancouver, Canada. 3. Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: pblack@mail.ubc.ca.
Abstract
OBJECTIVE: To evaluate the rates at which patients are offered and receive local salvage therapy (LST) after failure of primary radiotherapy for localized prostate cancer, as it is the only potentially curative treatment for localized recurrence but appears to be underutilized when compared with androgen-deprivation therapy (ADT) or observation. MATERIALS AND METHODS: Patients with localized prostate cancer who received primary radiotherapy with curative intent between 1999 and 2000 were identified in the British Columbia Tumour Registry. Exclusion criteria included patient age >72 years, prostate-specific antigen>40 ng/ml, and clinical stage T4 at diagnosis. Data on clinicopathologic features, primary therapy, prostate-specific antigen kinetics, and salvage therapy were collected retrospectively. Radiation failure was defined as biochemical recurrence according to the Phoenix criteria or by initiation of salvage therapy. RESULTS: Of 1,782 patients treated in the study period, 1,067 met inclusion criteria. Of these, 257 failed radiation therapy. Radiation therapy failure was managed with observation (>12 mo) in 126 patients and ADT in 119. Of the observed patients, 66 subsequently received ADT. Five patients (1.8%) received LST (3 radical prostatectomy and 2 brachytherapy). CONCLUSIONS: Only 2% of patients relapsing after radiation therapy for localized prostate cancer received LST. Although the benefits of LST are unproven, these findings reveal a possible underutilization of LST and indicate a need for enhanced collaboration between specialties to optimize care of this challenging cohort.
OBJECTIVE: To evaluate the rates at which patients are offered and receive local salvage therapy (LST) after failure of primary radiotherapy for localized prostate cancer, as it is the only potentially curative treatment for localized recurrence but appears to be underutilized when compared with androgen-deprivation therapy (ADT) or observation. MATERIALS AND METHODS:Patients with localized prostate cancer who received primary radiotherapy with curative intent between 1999 and 2000 were identified in the British Columbia Tumour Registry. Exclusion criteria included patient age >72 years, prostate-specific antigen>40 ng/ml, and clinical stage T4 at diagnosis. Data on clinicopathologic features, primary therapy, prostate-specific antigen kinetics, and salvage therapy were collected retrospectively. Radiation failure was defined as biochemical recurrence according to the Phoenix criteria or by initiation of salvage therapy. RESULTS: Of 1,782 patients treated in the study period, 1,067 met inclusion criteria. Of these, 257 failed radiation therapy. Radiation therapy failure was managed with observation (>12 mo) in 126 patients and ADT in 119. Of the observed patients, 66 subsequently received ADT. Five patients (1.8%) received LST (3 radical prostatectomy and 2 brachytherapy). CONCLUSIONS: Only 2% of patients relapsing after radiation therapy for localized prostate cancer received LST. Although the benefits of LST are unproven, these findings reveal a possible underutilization of LST and indicate a need for enhanced collaboration between specialties to optimize care of this challenging cohort.
Authors: Randall J Brenneman; Edward Soffen; Hiram A Gay; Peter F Orio; John P Christodouleas; John C Baumann; Brian C Baumann Journal: Transl Androl Urol Date: 2019-07
Authors: Juanita M Crook; Peixin Zhang; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Nadeem Pervez; Eric Vigneault; Charles Catton; Jeff Michalski; Mack Roach; David Beyer; Ashesh Jani; Eric Horwitz; Viroon Donavanik; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2018-10-09 Impact factor: 7.038
Authors: Juanita Crook; Joseph P Rodgers; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Albert D Murtha; Eric Vigneault; Joelle Helou; Jeff M Michalski; Mack Roach; David Beyer; Ashesh B Jani; Eric M Horwitz; Adam Raben; Stephanie Pugh; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-03 Impact factor: 7.038
Authors: Patrick A Kenney; Cayce B Nawaf; Mahmoud Mustafa; Sijin Wen; Matthew F Wszolek; Curtis A Pettaway; John F Ward; John W Davis; Louis L Pisters Journal: Can J Urol Date: 2016-06 Impact factor: 1.344
Authors: Khurram M Siddiqui; Michele Billia; Andrew Williams; Ali Alzahrani; Joseph L Chin Journal: Can Urol Assoc J Date: 2015 Sep-Oct Impact factor: 1.862
Authors: Brecht Devos; Walid Al Hajj Obeid; Colin Andrianne; Romain Diamand; Alexandre Peltier; Wouter Everaerts; Hein Van Poppel; Roland Van Velthoven; Steven Joniau Journal: World J Urol Date: 2019-01-21 Impact factor: 4.226